Somatostatin Analogues for Neuroendocrine Tumors

(REMAIN Trial)

This trial tests whether somatostatin analogues (SSAs), a type of medication, can manage neuroendocrine tumors more effectively than observation alone after certain radiation treatments. Participants will either receive SSA treatment or be monitored according to standard care guidelines. The trial targets individuals with specific neuroendocrine tumors, particularly those who have received or are receiving a specific radiation therapy called PRRT. For those with a confirmed diagnosis of a gastrointestinal or pancreatic neuroendocrine tumor that cannot be surgically removed, this trial might be suitable. As a Phase 3 trial, this research represents the final step before FDA approval, offering early access to potentially effective treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Studies have shown that somatostatin analogues (SSAs) are generally well-tolerated by patients. These treatments reduce the production of certain hormones, helping to manage symptoms caused by neuroendocrine tumors. Research indicates that serious side effects are rare with these treatments. Some patients might experience mild side effects, but these are usually manageable. SSAs already treat conditions like acromegaly (a hormonal disorder) and hormone-secreting tumors, demonstrating a good safety record. For those considering joining a trial using SSAs, past studies suggest they are relatively safe.¹²³⁴⁵

Most treatments for neuroendocrine tumors focus on surgery, chemotherapy, or radiation to manage the disease. However, somatostatin analogues (SSAs) are unique because they specifically mimic the action of the natural hormone somatostatin to inhibit excessive hormone secretion by the tumors. This targeted approach not only helps control symptoms but may also slow tumor growth. Researchers are excited about SSAs because they can be administered consistently over time and potentially offer a more tailored treatment option compared to conventional methods.

Research has shown that somatostatin analogues (SSAs) can effectively treat neuroendocrine tumors (NETs). These medications can slow cancer growth and sometimes shrink tumors. They also help manage symptoms like diarrhea and flushing, common in people with NETs. Some studies have found that patients taking SSAs experienced a longer period without disease progression. In one study, no patients on SSA treatment experienced tumor growth or died from the disease, highlighting its potential to stabilize the condition. In this trial, one group of participants will receive SSAs, while another group will undergo observation according to current standard care guidelines. Overall, SSAs are a well-established treatment that can help control symptoms and affect tumor growth.⁶⁷⁸⁹¹⁰